Skip to content
Biotechnology, Engineering

A better ‘map’ of the lights you see when you close your eyes can improve ‘bionic eye’ outcomes

Monash University 2 mins read
Monash University's Gennaris cortical implant

Researchers at Monash University have identified a new way of mapping ‘phosphenes’ – the visual perception of the bright flashes we see when no light is entering the eye – to improve the outcome of surgery for patients receiving a cortical visual prosthesis (‘bionic eye’).

 

Cortical visual prostheses are devices implanted onto the brain with the aim of restoring sight by directly stimulating the area responsible for vision, the visual cortex, bypassing damage to the retina of the eye or the optic nerve.

 

A typical prosthesis consists of an array of fine electrodes, each of which is designed to trigger a phosphene. Given the limited number of electrodes, understanding how electrodes can best be placed to generate useful perceived images becomes critical.

 

As part of this, researchers from the Department of Electrical and Computer Systems Engineering at Monash University, led by Associate Professor Yan Tat Wong, are honing in on the ideal distribution of phosphenes.

 

“Phosphenes are likely to be distributed unevenly in an individual’s visual field, and differences in the surface of the brain also affect how surgeons place implants, which together result in a phosphene map unique to each patient,” Associate Professor Wong said.

 

Published in the Journal of Neural Engineering, ‘A novel simulation paradigm utilising MRI-derived phosphene maps for cortical prosthetic vision’ presents a more realistic simulation for cortical prosthetic vision.

The study used a retinotopy dataset based on magnetic resonance imaging (MRI) scans, consulting with a neurosurgeon about realistic electrode implantation sites in different individuals, and applying a clustering algorithm to determine the most suitable regions to present stimuli.

 

Sighted participants recruited for the study were asked to test and verify the phosphene maps based on visual acuity and object recognition. 

 

“We’re proposing a new process that incorporates our simulation paradigm into surgical planning to help optimise the implantation of a cortical prosthesis,” Associate Professor Wong said.

 

The process would begin with an MRI scan to plot the recipient’s brain surface in the area of the visual cortex. Potential implant locations would then be identified, and the simulation developed in the Monash research would be used to plot phosphene maps.

 

“We can use the metrics we computed to find practical implant locations that are more likely to give us a usable phosphene map, and we can verify those options through psychophysics tests on sighted participants using a virtual reality headset,” Associate Professor Wong said.

 

“We believe this is the first approach that realistically simulates the visual experience of cortical prosthetic vision.” 

- ENDS -

 

MEDIA ENQUIRIES

Loretta Wylde

Monash University

Media and Communications

E: loretta.wylde@monash.edu

T: +61 (0) 432 123 106

 

GENERAL MEDIA ENQUIRIES

Monash Media

T: +61 (0) 3 9903 4840

E: media@monash.edu

For more Monash media stories, visit our news and events site 

Media

More from this category

  • Engineering, Science
  • 26/07/2024
  • 10:26
UNSW Sydney

Fresh light on the path to net zero

UNSW researchers are the first in the world to use magnetic fields to reveal the mystery of how light particles split – which could…

  • Contains:
  • Biotechnology, Business Company News
  • 24/07/2024
  • 10:53
Jane Morgan Management

LTR Pharma Ltd (ASX:LTP) Completes A$10.5 million Placement to Expedite Commercialisation of SPONTAN

Sydney, Australia – 24 July 2024 – LTR Pharma Limited (ASX: LTP) ("LTR Pharma" or "the Company"), a company focused on improving men’s health through the clinical development and commercialisation of an innovative nasal spray treatment for Erectile Dysfunction ("ED") called SPONTAN®, is pleased to announce the successful completion of a A$10.5 million share placement to sophisticated and new institutional investors. The placement received demand significantly above the A$10.5 million raised. Key Highlights: Successful Fundraising: LTR Pharma has raised A$10.5 million through a private placement at an issue price of A$0.73 per share, representing a 13.2% discount to the 30-day…

  • Contains:
  • Agriculture Farming Rural, Biotechnology
  • 23/07/2024
  • 15:56
La Trobe University

Nation’s food security tackled through new institute

La Trobe University is paving the way for Australian food security, with the establishment of a new institute that will expand cutting-edge agricultural research and innovation. The La Trobe Institute for Sustainable Agriculture and Food (LISAF) officially launched today (23 July), to undertake research and innovation across the agri-food-health chain, aiming to enhance profitability for producers while also improving product quality and choice for consumers. LISAF Director Professor Tony Bacic said a key component of the Institute’s “paddock to gut” research was to enhance plant functionality, enabling food and medicinal crops to be grown in innovative ways and with new…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.